| Quantity: | |
|---|---|
Broad model portfolio – Covers IgE-dependent (OVA), direct mast cell activator (C48/80), and passive sensitization (PCA) mechanisms.
Multiple species/strains – BALB/c, C57BL/6 mice and Wistar rats available.
Comprehensive endpoints – Body weight, eosinophil counts, serum IgE, mast cell degranulation, paw swelling, Evans blue extravasation, histopathology (HE, toluidine blue).
Translational value – Ideal for testing anti-IgE biologics, mast cell stabilizers, H1-antihistamines, and MRGPRX2 antagonists.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
OVA Induced BALB/c Urticaria Model
OVA Induced C57BL/6 Urticaria Model
C48/80 Induced BALB/c Acute Urticaria Model
DNP-IgE & DNFB Induced BALB/c PCA Model
OVA Induced Rat PCA Model
• Efficacy testing of immunomodulators (corticosteroids, mycophenolate, cyclophosphamide) for IgAN
• Evaluation of renoprotective agents and angiotensin-converting enzyme (ACE) inhibitors
• Target validation for IgA immune complex deposition and mesangial cell activation
• Biomarker discovery (albuminuria, serum IgA levels)
• IND-enabling pharmacology and toxicology studies
Model | Species/Strain | Induction Method | Key Endpoints | Study Duration |
OVA Induced BALB/c Urticaria Model | BALB/c mouse | OVA + alum sensitization + intradermal OVA challenge | Body weight, eosinophils, serum IgE, mast cell degranulation, HE score | 4–6 weeks |
OVA Induced C57BL/6 Urticaria Model | C57BL/6 mouse | OVA + alum sensitization + intradermal OVA challenge | Mast cell degranulation, serum IgE, eosinophils | 4–6 weeks |
C48/80 Induced BALB/c Acute Urticaria Model | BALB/c mouse | Intradermal C48/80 | Paw swelling, Evans blue extravasation | 30min – 24 h |
DNP-IgE & DNFB Induced BALB/c PCA Model | BALB/c mouse | Intradermal DNP-IgE + topical DNFB | Urticaria number, itch events | 24–48h |
| OVA Induced Rat PCA Model | Wistar rat | Intradermal OVA-sensitized serum + i.v. OVA with Evans blue | Ear thickness, Evans blue OD, mast cell degranulation | 24–48h |
Q: What are the differences between these urticaria models?
A: OVA models represent IgE-dependent, Th2-mediated chronic urticaria. C48/80 model is acute, directly activating mast cells via MRGPRX2, ideal for studying non-IgE mediated pathways. PCA models evaluate passive sensitization and are used for assessing anti-IgE therapies.
Q: Which model is best for testing anti-IgE biologics?
A: The PCA models (DNP-IgE induced or OVA rat PCA) are ideal for evaluating anti-IgE antibodies, as they directly measure IgE-mediated mast cell activation.
Q: Can these models be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different antigen doses, treatment timing)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: OVA models require 4–6 weeks; C48/80 and PCA models are acute (hours to days), allowing rapid screening.
